CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Inclusion Criteria: * All subjects must have the ability to understand and the willingness to sign a written informed consent * Age 18 and older * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (corresponds to Karnofsky Performance Status \[KPS\] of \>= 70) * Life expectancy greater than 16 weeks * Relapsed/refractory disease; patients must have failed \>= 2 prior systemic therapies and have no treatment options known to provide clinical benefit * Biopsy confirmed relapsed or refractory B-cell lymphoma of the following subtypes; patients with a partial response to a previous treatment are allowed. * Follicular grade 1 or 2, or 3 marginal zone or small lymphocytic lymphoma * Diffuse large B-cell lymphoma, non-germinal center B-cell like (GCB) type determined by immunohistochemistry using Han's algorithm * Mantle cell lymphoma * Patients must have at least two separate tumor sites, one of which is at least 2 cm in diameter and peripherally accessible and amenable for intratumoral injection of CAS3/SS3 with stabilization by palpation, and the other is at least 1.5 cm in diameter * Tumor specimens must be available for immunological studies either from a previous biopsy or a new biopsy obtained before the initiation of the study. Paraffin-embedded specimens are acceptable * Required wash out periods for prior therapy: * Topical therapy: 2 weeks * Chemotherapy: 4 weeks * Radiotherapy: 4 weeks * Other investigational therapy: 4 weeks * Mon…